Form 4: Lyra Therapeutics CEO Maria Palasis Acquires 183,333 Shares Through Performance Stock Option Vesting

Lyra Therapeutics CEO Maria Palasis acquired 183,333 shares through the vesting of a performance stock option.

Summary

• Lyra Therapeutics CEO, Maria Palasis, acquired 183,333 shares of common stock through the vesting of a performance stock option.
• The performance stock option was granted on March 21, 2024, for a total of 550,000 shares, with vesting contingent on achieving certain milestones.
• On December 9, 2024, the company determined that Milestone 1 was achieved, resulting in the vesting of 183,333 shares.
• These vested shares will become exercisable on January 31, 2028.

Sentiment

Score: 7

Explanation: The document reflects a positive event (milestone achievement) and standard executive compensation practices, indicating a moderately positive sentiment.

Positives

• The vesting of the performance stock option indicates that the company has achieved a key milestone.
• The acquisition of shares by the CEO aligns her interests with those of the shareholders.

Future Outlook

The remaining performance stock options will vest upon the achievement of further milestones.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, aligning their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Performance-based stock options are a common form of executive compensation in the biotechnology industry, similar to companies like Amgen, Regeneron, and Biogen.
• The vesting schedule tied to milestones is also a typical approach to ensure that executives are rewarded for achieving specific company goals, similar to other companies in the sector.

Stakeholder Impact

• Shareholders may view the vesting of the performance stock option as a positive sign of the company's progress.
• The CEO's increased stake in the company aligns her interests with those of the shareholders.

Next Steps

• The remaining performance stock options will vest upon the achievement of further milestones.
• The vested shares will become exercisable on January 31, 2028.

Key Dates

Keywords

Performance Stock Option, Stock Vesting, Share Acquisition, CEO, Lyra Therapeutics, Incentive Award Plan